Literature DB >> 27883176

miR-429 is involved in regulation of NF-κBactivity by targeting IKKβ and suppresses oncogenic activity in cervical cancer cells.

Jing-Yi Fan1, Ya-Jie Fan1, Xiang-Ling Wang1, Hong Xie1, Hui-Jie Gao1, Yi Zhang1, Min Liu1, Hua Tang1.   

Abstract

Dysregulation of microRNAs (miRNAs) can contribute to tumorigenesis in cancers. In this study, we found that miR-429 was downregulated in cervical cancer (CC) tissues and suppressed cell viability and proliferation while promoting apoptosis in CC cells. IKKβ was a novel target gene of miR-429 and ectopic expression of IKKβ abrogated the phenotypes induced by miR-429. When IKKβ was downregulated by miR-429, nuclear factor κB (NF-κB) pathway activation, interleukin-6 (IL-6), and interferon-β (IFN-β) production were decreased in CC cells. These findings indicate that miR-429 is involved in regulation of the NF-κB pathway by targeting IKKβ and functions as a tumor suppressor in cervical carcinogenesis.
© 2016 Federation of European Biochemical Societies.

Entities:  

Keywords:  IKKβ; NF-κB; cervical cancer; miR-429

Mesh:

Substances:

Year:  2016        PMID: 27883176     DOI: 10.1002/1873-3468.12502

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  19 in total

Review 1.  Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: A review.

Authors:  Javid Sadri Nahand; Mohsen Moghoofei; Arash Salmaninejad; Zahra Bahmanpour; Mohammad Karimzadeh; Mitra Nasiri; Hamid Reza Mirzaei; Mohammad Hossein Pourhanifeh; Farah Bokharaei-Salim; Hamed Mirzaei; Michael R Hamblin
Journal:  Int J Cancer       Date:  2019-10-31       Impact factor: 7.396

2.  MicroRNA-429 inhibits cancer cell proliferation and migration by targeting AKT1 in renal cell carcinoma.

Authors:  Zhengming Su; Ganggang Jiang; Jinlan Chen; Xing Liu; Haibo Zhao; Zhiyuan Fang; Yongzhong He; Xianhan Jiang; Guibin Xu
Journal:  Mol Clin Oncol       Date:  2019-10-25

3.  miR-429 mediates tumor growth and metastasis in colorectal cancer.

Authors:  Yantao Han; Qian Zhao; Jie Zhou; Rui Shi
Journal:  Am J Cancer Res       Date:  2017-02-01       Impact factor: 6.166

Review 4.  MicroRNAs in gynecological cancers: Small molecules with big implications.

Authors:  Sanjeev K Srivastava; Aamir Ahmad; Haseeb Zubair; Orlandric Miree; Seema Singh; Rodney P Rocconi; Jennifer Scalici; Ajay P Singh
Journal:  Cancer Lett       Date:  2017-05-24       Impact factor: 8.679

Review 5.  Cervical cancer development, chemoresistance, and therapy: a snapshot of involvement of microRNA.

Authors:  Tandrima Mitra; Selvakumar Elangovan
Journal:  Mol Cell Biochem       Date:  2021-08-28       Impact factor: 3.396

6.  Exosomal transfer of miR-429 confers chemoresistance in epithelial ovarian cancer.

Authors:  Taoqiong Li; Li Lin; Qin Liu; Wujiang Gao; Lu Chen; Chunli Sha; Qi Chen; Wenlin Xu; Yuefeng Li; Xiaolan Zhu
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

7.  MicroRNA-30e Functions as a Tumor Suppressor in Cervical Carcinoma Cells through Targeting GALNT7.

Authors:  Huijuan Wu; Jun Chen; Dan Li; Xiangyu Liu; Lei Li; Ke Wang
Journal:  Transl Oncol       Date:  2017-09-27       Impact factor: 4.243

8.  MiR-429 Regulated by Endothelial Monocyte Activating Polypeptide-II (EMAP-II) Influences Blood-Tumor Barrier Permeability by Inhibiting the Expressions of ZO-1, Occludin and Claudin-5.

Authors:  Liangyu Chen; Yixue Xue; Jian Zheng; Xiaobai Liu; Jing Liu; Jiajia Chen; Zhen Li; Zhuo Xi; Hao Teng; Ping Wang; Libo Liu; Yunhui Liu
Journal:  Front Mol Neurosci       Date:  2018-02-07       Impact factor: 5.639

9.  Knockdown of USF1 Inhibits the Vasculogenic Mimicry of Glioma Cells via Stimulating SNHG16/miR-212-3p and linc00667/miR-429 Axis.

Authors:  Di Wang; Jian Zheng; Xiaobai Liu; Yixue Xue; Libo Liu; Jun Ma; Qianru He; Zhen Li; Heng Cai; Yunhui Liu
Journal:  Mol Ther Nucleic Acids       Date:  2019-01-15       Impact factor: 8.886

Review 10.  MicroRNA Roles in the Nuclear Factor Kappa B Signaling Pathway in Cancer.

Authors:  Jin'en Wu; Juntao Ding; Jing Yang; Xiaola Guo; Yadong Zheng
Journal:  Front Immunol       Date:  2018-03-19       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.